Vosoritide Phase 2 Trial in Idiopathic Short Stature Now Recruiting

A Phase 2 clinical trial of vosoritide was listed as recruiting as of May 22, 2026. The study, titled "A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature," is registered under identifier NCT06382155. Vosoritide is an approved compound, and this trial is examining its use in a pediatric population with idiopathic short stature, a use distinct from its current approved indication. The trial status is listed as recruiting, meaning the study is currently enrolling participants. No results or outcomes have been posted for this trial as of the listed date. The trial record does not provide additional details on enrollment numbers, dosing, or study design beyond phase and status designations. This update reflects only the recruitment status recorded in the trial registry entry and does not indicate any findings about safety or effectiveness. Readers interested in additional detail can consult the official trial listing for further information as it becomes available. For general background on this compound, see the compound overview.